Xilio Therapeutics, Inc. (XLO) analyst actions
Rating and price-target actions on XLO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the XLO overview →
2 measured XLO analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead | Press release | +6.34% | +1.90% | |
| Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data | Press release | +8.89% | +8.89% |
Keep exploring
More XLO: earnings → · SEC filings → · XLO overview →